Therapy for relapsed multiple myeloma

Mohammed A. Aljama; M. Hasib Sidiqi; David Dingli

doi:10.23736/S0031-0808.18.03542-5

Therapy for relapsed multiple myeloma

Mohammed A. Aljama, M. Hasib Sidiqi, David Dingli

Hematology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.

Original language	English (US)
Pages (from-to)	174-184
Number of pages	11
Journal	Panminerva Medica
Volume	60
Issue number	4
DOIs	https://doi.org/10.23736/S0031-0808.18.03542-5
State	Published - Dec 2018

Keywords

Multiple myeloma
Recurrence
Therapeutics

ASJC Scopus subject areas

General Medicine

Access to Document

10.23736/S0031-0808.18.03542-5

Cite this

@article{47f37eb308774cb69693f9a2af209cb0,

title = "Therapy for relapsed multiple myeloma",

abstract = "Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.",

keywords = "Multiple myeloma, Recurrence, Therapeutics",

author = "Aljama, {Mohammed A.} and Sidiqi, {M. Hasib} and David Dingli",

note = "Publisher Copyright: {\textcopyright} 2018 EDIZIONI MINERVA MEDICA.",

year = "2018",

month = dec,

doi = "10.23736/S0031-0808.18.03542-5",

language = "English (US)",

volume = "60",

pages = "174--184",

journal = "Panminerva Medica",

issn = "0031-0808",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "4",

}

TY - JOUR

T1 - Therapy for relapsed multiple myeloma

AU - Aljama, Mohammed A.

AU - Sidiqi, M. Hasib

AU - Dingli, David

PY - 2018/12

Y1 - 2018/12

N2 - Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.

AB - Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.

KW - Multiple myeloma

KW - Recurrence

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85058880614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058880614&partnerID=8YFLogxK

U2 - 10.23736/S0031-0808.18.03542-5

DO - 10.23736/S0031-0808.18.03542-5

M3 - Review article

C2 - 30303355

AN - SCOPUS:85058880614

SN - 0031-0808

VL - 60

SP - 174

EP - 184

JO - Panminerva Medica

JF - Panminerva Medica

IS - 4

ER -

Therapy for relapsed multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this